A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in the United States.

Trial Profile

A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in the United States.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2013

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Jul 2008 Actual completion date (May 2008) added as reported by ClinicalTrials.gov.
    • 09 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 23 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top